Coeptis Therapeutics, Inc. (COEP)
Company Description
Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer.
Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies.
The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease.
Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Country | United States |
Founded | 2017 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 4 |
CEO | Mr. David Mehalick |
Contact Details
Address:
105 Bradford Rd, Suite 420 Wexford, Pennsylvania 15090 United States | |
Phone | 724-934-6467 |
Website | coeptispharma.com |
Stock Details
Ticker Symbol | COEP |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001819663 |
CUSIP Number | 19207C104 |
ISIN Number | US19207C1045 |
Employer ID | 84-3998117 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
David Mehalick | Co-Founder, Chairman, Chief Executive Officer and Pres |
Christine Elise Sheehy | Co-Founder, Chief Financial Officer and Secretary |
Daniel Alexander Yerace | Co-Founder, Vice President of Operations and Director |
Gary R. Conte | Senior Vice President of Sales and Marketing |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 14, 2022 | 15-12G | Securities registration termination |
Nov 8, 2022 | 10-Q | Quarterly Report |
Oct 28, 2022 | 8-K | Current Report |
Sep 30, 2022 | DEFM14A | Filing |
Sep 21, 2022 | 8-K | Current Report |
Sep 21, 2022 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Sep 19, 2022 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Sep 16, 2022 | PREM14A | Filing |
Sep 7, 2022 | 253G2 | Acc-no: 0001493152-21-027927 (33 Act) |
Sep 7, 2022 | 8-K | Current Report |